Echosensa high-tech company and provider of the FibroScan®-Solutions Portfolios, is pleased to announce that it is within the guidelines of the American Association of Clinical Endocrinology for clinical practice for the diagnosis and management of nonalcoholic fatty liver disease in the primary care and endocrinology clinical settings that is, transient elastography (TE) for quantifying liver fat (CAP) and fibrosis and vibration-controlled transient elastography (VCTE) for risk stratification are preferable. It is very clear from these guidelines that physicians should use VCTE – such as FibroScan – to grade the risk of fibrosis in people with non-alcoholic fatty liver disease (NAFL) because it is the best way to identify advanced disease and most predictive of liver treatment outcomes can become.
For more information, please refer to the information sheet:
“This technology provides an ideal means of early identification of high-risk patients to prevent the development of cirrhosis and comorbidities based on screening measures for patients at risk of liver fibrosis (FIB-4),” stated Dominique Legros, Group CEO, Echosens. “Following this, further plasma biomarkers should be determined and/or liver imaging based on stratification of fibrosis risk into low, indeterminate, or high risk of developing future cirrhosis, with referral to a hepatologist for patients in the higher risk groups.”
As a pioneer in liver elastography, FibroScan is recognized worldwide as the non-invasive gold standard for evaluating liver fibrosis and steatosis. There are more than 3,500 specialist publications on this subject. The non-invasive technology provides a rapid quantitative assessment of liver stiffness and controlled attenuation parameters (CAP) at the point of care, associated with liver fibrosis and hepatic fat, respectively.
AACE guidelines also recommend that repeat testing be considered every two years in low-risk patients because one study showed that only a minority will progress to a higher stage of fibrosis within this timeframe.
Legros added: “Early detection is important because early intervention can halt or reverse disease progression. According to a recent study referenced in the guidelines, in patients with type 2 diabetes, screening for NAFL followed by intensive lifestyle interventions was a cost-effective approach that further supported screening recommendations. VCTE is the most commonly used non-invasive method for LSM and therefore for determining the risk of liver fibrosis and ultimately ruling out cirrhosis.”
Because NAFL is usually asymptomatic, point-of-care testing, monitoring, and ongoing assessment of liver fat content and liver stiffness, as possible with FibroScan, may be more cost-effective to identify patients whose liver damage is asymptomatic and undiagnosed. FibroScan can also provide readings to monitor changes in liver fat caused by lifestyle changes.
Jon Gingrich, CEO, Echosens North America, added: “We are very excited about this research and the broad consensus that early detection and early intervention is warranted in obesity, prediabetes, dyslipidemia and hypertension. The VCTE provided by FibroScan is inexpensive, safe and enables interventions to prevent diabetes complications and cardiovascular events.”
As a pioneer in its field, Echosens has the practice of liver assessment with FibroScan®, the non-invasive solution for comprehensive liver health management. FibroScan® is recognized worldwide and validated by over 3,500 specialist publications and 160 international guidelines. Echosens introduces FibroScan® Available in more than 100 countries, enabling millions of liver exams worldwide. https://www.echosens.com/
The source language in which the original text is published is the official and authorized version. Translations will be included for a better understanding. Only the language version that was originally published is legally valid. Therefore, compare translations with the original language version of the publication.
201.641.1911, App. 14
© Business Wire, Inc.
Notice of Use
This material is not editorial content of AFP. AFP is not responsible for the accuracy of the content. If you have any questions about the content of this notice, please contact the person named in the text.